Queen Mary's Strategy 2030 sets out our aim to be the most inclusive research-intensive university in the world. In the most recent national assessment of research - the Research Excellence Framework (REF 2014) - we were ranked 5th in the UK for our 3* and 4* research outputs.
Queen Mary's annual research income (excluding capital grants) is ￡104.9m.
Many of our large awards are held jointly with other universities and cultural institutions, enabling the sharing of specialist knowledge and facilitating multi-disciplinary collaboration.
Read about our major grants.
We have done exceptionally well in external assessments of our research. Our Drama and Linguistics departments came top in the country, English was placed 5th, and the following research areas were placed in the top 10 for their outputs: Chemistry (6th equal), Clinical Medicine and Public Health (6th), Computer Science (10th), Electronic Engineering (9th equal), Engineering (7th equal) and Geography (8th equal) (Times Higher Education).
As a large multi-disciplinary university, we have strengths in many different disciplines, which enables interesting and constructive collaborative work. Our research centres formalise these valuable interdisciplinary links.
We also enjoy strategic partnerships with academics in other universities, as well as strong links with cultural institutions.
Research informs our teaching at all levels - whether that is inspiring undergraduates or supporting PhD students in actively contributing to the body of knowledge in their chosen field.
Student satisfaction with the quality of teaching at Queen Mary remains consistently high. In the 2016 National Student Survey Queen Mary ranked top in London among Russell Group universities. A number of our subject areas received over 90 per cent for overall satisfaction; these include Medicine, Dentistry, Law and English.
Generating new business
Much of our research has commercial potential, and we actively seek ways to bring it to the market place. Our latest licensing opportunities are available at Queen Mary Innovation Ltd - a company devoted to providing a wide range of services in support of business-academic partnerships, from technology licensing to spin-out activities.
Queen Mary's spin-out success stories include ApaTech Ltd, a company specialising in synthetic bone graft material which was sold in March 2010 to Baxter International for up to $330 million. Major Queen Mary spin-outs are hvivo Ltd, and Actual Experience. Another spinout with origins at Queen Mary, Monoidics, was bought by Facebook in 2013. New spinouts include Augmented Instruments Ltd, commercialising our digitial audio technology, and Pronostics Ltd, providing technology to profile patients for cancer treatment. The aggregate value of the companies in the Queen Mary spinout portfolio is approaching ￡300m.